Energetic and cell membrane metabolic products in patients with primary Insomnia: A 31-Phosphorus magnetic resonance spectroscopy study at 4 Tesla

Sleep

Volumn 36, Issue 4, 2013, Pages 493-500

  Harper, David G ^a,c   Plante, David T ^d   Jensen, J Eric ^a,c   Ravichandran, Caitlin ^a,c   Buxton, Orfeu M ^b,c   Benson, Kathleen L ^a   Oconnor, Shawn P ^b   Renshaw, Perry F ^e   Winkelman, John W ^b,c  

^a MCLEAN HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

Adenosine triphosphate (ATP); Long term potentiation; Phosphocholine; Phosphocreatine; Sleep; Spectroscopy

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA NUCLEOSIDE TRIPHOSPHATE; CREATININE; CREATININE PHOSPHORIC ACID; NUCLEOSIDE TRIPHOSPHATE; PHOSPHATIDYLCHOLINE; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOENERGY; BRAIN METABOLISM; CELL ENERGY; CELL MEMBRANE METABOLISM; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPOTHESIS; INSOMNIA; INTERVIEW; MALE; METABOLITE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIMARY INSOMNIA; PRIORITY JOURNAL; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; UNIVERSITY HOSPITAL; WHITE MATTER;

ADENOSINE TRIPHOSPHATE (ATP); LONG-TERM POTENTIATION; PHOSPHOCHOLINE; PHOSPHOCREATINE; SLEEP; SPECTROSCOPY;

ADENOSINE TRIPHOSPHATE; ADULT; BIOLOGICAL MARKERS; BRAIN; CELL MEMBRANE; CROSS-SECTIONAL STUDIES; ENERGY METABOLISM; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHOCREATINE; PHOSPHORUS ISOTOPES; POLYSOMNOGRAPHY; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84875734213     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.2530     Document Type: Article

References (43)

1. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-23.
2. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111.
3. Perlis ML, Giles DE, Mendelson WB, Bootzin RR, Wyatt JK. Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. J Sleep Res 1997;6:179-88.
4. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev 2010;14:19-31.
5. Nofzinger EA, Buysse DJ, Germain A, Price JC, Miewald JM, Kupfer DJ. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004;161:2126-8.
6. Nofzinger EA, Nissen C, Germain A, et al. Regional cerebral metabolic correlates of WASO during NREM sleep in insomnia. J Clin Sleep Med 2006;2:316-22.
7. Winkelman JW, Buxton OM, Jensen JE, et al. Reduced brain GABA in primary insomnia: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS). Sleep 2008;31:1499-506.
8. Renshaw PF, Parow AM, Hirashima F, et al. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry 2001;158:2048-55.
9. Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry 2008;63:1127-34.
10. Hoang TQ, Bluml S, Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998;50:1033-40.
11. Klunk WE, Xu C, Panchalingam K, McClure RJ, Pettegrew JW. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol Aging 1996;17:349-57.
12. Kato T, Shioiri T, Murashita J, et al. Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS. Psychol Med 1995;25:557-66.
13. Jensen JE, Al-Semaan YM, Williamson PC, et al. Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31) P-MRS study at 4.0 Tesla. Br J Psychiatry 2002;180:39-44.
14. Jensen JE, Drost DJ, Menon RS, Williamson PC. In vivo brain (31)PMRS: measuring the phospholipid resonances at 4 Tesla from small voxels. NMR Biomed 2002;15:338-47.
15. Jensen JE, Daniels M, Haws C, et al. Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients. Exp Clin Psychopharmacol 2008;16:199-206.
16. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001;20:45-57.
17. Venables WN, Ripley BD. Modern applied statistics with S. 4 ed. New York: Springer, 2002.
18. Forester BP, Harper DG, Jensen JE, et al. 31Phosphorus magnetic resonance spectroscopy study of tissue specific changes in high energy phosphates before and after sertraline treatment of geriatric depression. Int J Geriatr Psychiatry 2009;24;788-97.
19. Doyle TJ, Bedell BJ, Narayana PA. Relative concentrations of proton MR visible neurochemicals in gray and white matter in human brain. Magn Reson Med 1995;33:755-9.
20. Mason GF, Chu WJ, Vaughan JT, et al. Evaluation of 31P metabolite differences in human cerebral gray and white matter. Magn Reson Med 1998;39:346-53.
21. Hetherington HP, Spencer DD, Vaughan JT, Pan JW. Quantitative (31)P spectroscopic imaging of human brain at 4 Tesla: assessment of gray and white matter differences of phosphocreatine and ATP. Magn Reson Med 2001;45:46-52.
22. Erecinska M, Silver IA. ATP and brain function. J Cereb Blood Flow Metab 1989;9:2-19.
23. King LJ, Lowry OH, Passonneau JV, Venson V. Effects of convulsants on energy reserves in the cerebral cortex. J Neurochem 1967;14:599-611.
24. Blennow G, Folbergrova J, Nilsson B, Siesjo BK. Cerebral metabolic and circulatory changes in the rat during sustained seizures induced by DLhomocysteine. Brain Res 1979;179:129-46.
25. Meyer RA, Sweeney HL, Kushmerick MJ. A simple analysis of the "phosphocreatine shuttle". Am J Physiol 1984;246:C365-77.
26. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
27. Altena E, Vrenken H, Van Der Werf YD, van den Heuvel OA, Van Someren EJ. Reduced orbitofrontal and parietal gray matter in chronic insomnia: a voxel-based morphometric study. Biol Psychiatry 2010;67:182-5.
28. Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry 1997;154:116-8.
29. Volz HP, Rzanny R, Riehemann S, et al. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci 1998;248:289-95.
30. Kato T, Takahashi S, Shioiri T, Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1992;26:223-30.
31. Kato T, Takahashi S, Shioiri T, Murashita J, Hamakawa H, Inubushi T. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1994;31:125-33.
32. Turek FW. Insomnia and depression: if it looks and walks like a duck. Sleep 2005;28:1362-3.
33. Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? J Affect Disord 2003:76;255-9.
34. Riemann D, Workshop P. Does effective management of sleep disorders reduce depressive symptoms and the risk of depression? Drugs 2009;69: 43-64.
35. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ. Epidemiology of insomnia, depression, and anxiety. Sleep 2005;28:1457-64.
36. Biver F, Goldman S, Delvenne V, et al. Frontal and parietal metabolic disturbances in unipolar depression. Biol Psychiatry 1994;36:381-8.
37. Kimbrell TA, Ketter TA, George MS, et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry 2002;51:237-52.
38. Hosokawa T, Momose T, Kasai K. Brain glucose metabolism difference between bipolar and unipolar mood disorders in depressed and euthymic states. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:243-50.
39. Morash SC, Cook HW, Spence MW. Phosphatidylcholine metabolism in cultured cells: catabolism via glycerophosphocholine. Biochim Biophys Acta 1988;961:194-202.
40. Baburina I, Jackowski S. Cellular responses to excess phospholipid. J Biol Chem 1999;274:9400-8.
41. Balsinde J, Balboa MA. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell Signal 2005;17:1052-62.
42. Barbour SE, Kapur A, Deal CL. Regulation of phosphatidylcholine homeostasis by calcium-independent phospholipase A2. Biochim Biophys Acta 1999;1439:77-88.
43. Babb SM, Wald LL, Cohen BM, et al. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl) 2002;161:248-54.